Medication Adherence: Its Importance in Cardiovascular Outcomes

By P. M. Ho, Christopher Bryson, John S. Rumsfeld. Circulation, 2009

1,558 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Family Practice, Geriatrics and Gerontology

View Paper: https://www.semanticscholar.org/paper/6694bbe517127e5e8ce6245fdd6d2c39b829bf38

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

In Family Practice

In Geriatrics and Gerontology

Citations in the corpus

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “After 1 year, ,50% of patients report persistent use of statins, beta-blockers, or antihypertensive therapy.(518,519)”
Adherence to Therapies in Patients with Type 2 Diabetes (2013, background): “These measures correlate with the quantity of doses prescribed, but not their actual administration or timing [11].”
Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis. (2016, methodology): “Study Eligibility We included trials based on the following criteria: (1) the trial studied adult patients (≥18 years) with chronic disease, (2) the patients received a mobile telephone text message intervention designed to promote medication adherence, (3) the design was a randomized clinical trial”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “The reasons for poor adherence are multifactorial (Table F in web addenda).(483)”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “The reasons for poor adherence are multifactorial (Table F in web addenda).(483)”
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, background): “Prevalence and costs of non-adherence Medication non-adherence is thought to account for 30– 50% of treatment failures and a variety of adverse medical treatment outcomes, including increased hospitalization rates and institutionalization for the frail elderly as well as increased healthcare costs.(”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “The reasons for poor adherence are multifactorial (Table F in web addenda) [483].”